<VariationArchive VariationID="6003" VariationName="NM_014251.3(SLC25A13):c.1638_1660dup (p.Ala554fs)" VariationType="Duplication" Accession="VCV000006003" Version="49" RecordType="classified" NumberOfSubmissions="11" NumberOfSubmitters="10" DateLastUpdated="2024-06-23" DateCreated="2013-04-04" MostRecentSubmission="2024-06-17">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="21042" VariationID="6003">
      <GeneList>
        <Gene Symbol="SLC25A13" FullName="solute carrier family 25 member 13" GeneID="10165" HGNC_ID="HGNC:10983" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>7q21.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="7" Accession="NC_000007.14" start="96120220" stop="96322098" display_start="96120220" display_stop="96322098" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="7" Accession="NC_000007.13" start="95749531" stop="95951458" display_start="95749531" display_stop="95951458" Strand="-" />
          </Location>
          <OMIM>603859</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_014251.3(SLC25A13):c.1638_1660dup (p.Ala554fs)</Name>
      <CanonicalSPDI>NC_000007.14:96121928:CCCGGGCAGCCACCTGTAATCTC:CCCGGGCAGCCACCTGTAATCTCCCCGGGCAGCCACCTGTAATCTC</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>7q21.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="7" Accession="NC_000007.14" start="96121928" stop="96121929" display_start="96121928" display_stop="96121929" variantLength="23" positionVCF="96121928" referenceAlleleVCF="G" alternateAlleleVCF="GCCCGGGCAGCCACCTGTAATCTC" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="7" Accession="NC_000007.13" start="95751240" stop="95751241" display_start="95751240" display_stop="95751241" variantLength="23" positionVCF="95751240" referenceAlleleVCF="G" alternateAlleleVCF="GCCCGGGCAGCCACCTGTAATCTC" />
      </Location>
      <OtherNameList>
        <Name>1638ins23</Name>
        <Name>p.Ala554Glyfs*17</Name>
      </OtherNameList>
      <ProteinChange>A555fs</ProteinChange>
      <ProteinChange>A554fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000007.13" sequenceAccession="NC_000007" sequenceVersion="13" change="g.95751241_95751263dup" Assembly="GRCh37">
            <Expression>NC_000007.13:g.95751241_95751263dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000007.14" sequenceAccession="NC_000007" sequenceVersion="14" change="g.96121929_96121951dup" Assembly="GRCh38">
            <Expression>NC_000007.14:g.96121929_96121951dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_012247.2" sequenceAccession="NG_012247" sequenceVersion="2" change="g.205197_205219dup">
            <Expression>NG_012247.2:g.205197_205219dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001160210.2" sequenceAccession="NM_001160210" sequenceVersion="2" change="c.1641_1663dup">
            <Expression>NM_001160210.2:c.1641_1663dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001153682.1" sequenceAccession="NP_001153682" sequenceVersion="1" change="p.Ala555fs">
            <Expression>NP_001153682.1:p.Ala555fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_014251.3" sequenceAccession="NM_014251" sequenceVersion="3" change="c.1638_1660dup" MANESelect="true">
            <Expression>NM_014251.3:c.1638_1660dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_055066.1" sequenceAccession="NP_055066" sequenceVersion="1" change="p.Ala554fs">
            <Expression>NP_055066.1:p.Ala554fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="NR_027662.2" sequenceAccession="NR_027662" sequenceVersion="2" change="n.1664_1686dup">
            <Expression>NR_027662.2:n.1664_1686dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001619" Type="non-coding transcript variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_014251.2" sequenceAccession="NM_014251" sequenceVersion="2" change="c.1638_1660dup23">
            <Expression>NM_014251.2:c.1638_1660dup23</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA340497" DB="ClinGen" />
        <XRef Type="Allelic variant" ID="603859.0003" DB="OMIM" />
        <XRef Type="rs" ID="80338725" DB="dbSNP" />
      </XRefList>
      <AlleleFrequencyList>
        <AlleleFrequency Value="0.00001" Source="The Genome Aggregation Database (gnomAD)" />
        <AlleleFrequency Value="0.00009" Source="Exome Aggregation Consortium (ExAC)" />
        <AlleleFrequency Value="0.00009" Source="The Genome Aggregation Database (gnomAD), exomes" />
      </AlleleFrequencyList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_014251.3(SLC25A13):c.1638_1660dup (p.Ala554fs) AND Citrullinemia type II" Accession="RCV000006371" Version="8">
        <ClassifiedConditionList TraitSetID="1661">
          <ClassifiedCondition DB="MedGen" ID="C1863844">Citrullinemia type II</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-02-24" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_014251.3(SLC25A13):c.1638_1660dup (p.Ala554fs) AND not provided" Accession="RCV000726889" Version="10">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2022-08-11" SubmissionCount="3">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_014251.3(SLC25A13):c.1638_1660dup (p.Ala554fs) AND Citrullinemia, type II, adult-onset" Accession="RCV002259302" Version="4">
        <ClassifiedConditionList TraitSetID="65850">
          <ClassifiedCondition DB="MedGen" ID="CN295299">Citrullinemia, type II, adult-onset</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-03-28" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_014251.3(SLC25A13):c.1638_1660dup (p.Ala554fs) AND Citrin deficiency" Accession="RCV000822371" Version="7">
        <ClassifiedConditionList TraitSetID="9638">
          <ClassifiedCondition DB="MedGen" ID="C1997910">Citrin deficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-01-29" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_014251.3(SLC25A13):c.1638_1660dup (p.Ala554fs) AND Neonatal intrahepatic cholestasis due to citrin deficiency" Accession="RCV001004526" Version="7">
        <ClassifiedConditionList TraitSetID="1662">
          <ClassifiedCondition DB="MedGen" ID="C1853942">Neonatal intrahepatic cholestasis due to citrin deficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2022-06-30" SubmissionCount="3">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-03-28" NumberOfSubmissions="11" NumberOfSubmitters="10" DateCreated="2013-04-04" MostRecentSubmission="2024-06-17">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">10369257</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">11432966</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">14680984</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">19413723</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21424115</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23067347</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23901231</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27405544</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">30098237</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">31450232</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">34295780</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">36599957</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8105687</ID>
        </Citation>
        <Citation Type="general">
          <URL>http://www.egl-eurofins.com/emvclass/emvclass.php?approved_symbol=SLC25A13</URL>
        </Citation>
        <Citation Type="review" Abbrev="GeneReviews">
          <ID Source="PubMed">20301360</ID>
          <ID Source="BookShelf">NBK1181</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="65850" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="55843" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Citrullinemia, type II, adult-onset</ElementValue>
                <XRef ID="MONDO:0011326" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Adult-onset citrullinemia type 2</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CTLN2</ElementValue>
                <XRef Type="MIM" ID="603471" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Citrin deficiency can manifest in newborns or infants as neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD), in older children as failure to thrive and dyslipidemia caused by citrin deficiency (FTTDCD), and in adults as recurrent hyperammonemia with neuropsychiatric symptoms in citrullinemia type II (CTLN2). Often citrin deficiency is characterized by strong preference for protein-rich and/or lipid-rich foods and aversion to carbohydrate-rich foods. NICCD. Children younger than age one year have a history of low birth weight with growth restriction and transient intrahepatic cholestasis, hepatomegaly, diffuse fatty liver, and parenchymal cellular infiltration associated with hepatic fibrosis, variable liver dysfunction, hypoproteinemia, decreased coagulation factors, hemolytic anemia, and/or hypoglycemia. NICCD is generally not severe and symptoms often resolve by age one year with appropriate treatment, although liver transplantation has been required in rare instances. FTTDCD. Beyond age one year, many children with citrin deficiency develop a protein-rich and/or lipid-rich food preference and aversion to carbohydrate-rich foods. Clinical abnormalities may include growth restriction, hypoglycemia, pancreatitis, severe fatigue, anorexia, and impaired quality of life. Laboratory changes are dyslipidemia, increased lactate-to-pyruvate ratio, higher levels of urinary oxidative stress markers, and considerable deviation in tricarboxylic acid (TCA) cycle metabolites. One or more decades later, some individuals with NICCD or FTTDCD develop CTLN2. CTLN2. Presentation is sudden and usually between ages 20 and 50 years. Manifestations are recurrent hyperammonemia with neuropsychiatric symptoms including nocturnal delirium, aggression, irritability, hyperactivity, delusions, disorientation, restlessness, drowsiness, loss of memory, flapping tremor, convulsive seizures, and coma. Symptoms are often provoked by alcohol and sugar intake, medication, and/or surgery. Affected individuals may or may not have a prior history of NICCD or FTTDCD.</Attribute>
                <XRef ID="NBK1181" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301360</ID>
                <ID Source="BookShelf">NBK1181</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Citrullinemia_II_Transition.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Transition to Adult Health Care ACT Sheet, Citrin Deficiency, Citrullinemia II, Urea Cycle Disorder, 2012</CitationText>
              </Citation>
              <XRef ID="247585" DB="Orphanet" />
              <XRef ID="CN295299" DB="MedGen" />
              <XRef ID="MONDO:0011326" DB="MONDO" />
              <XRef Type="MIM" ID="603471" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="1661" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="973" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Citrullinemia type 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Citrullinemia type II</ElementValue>
                <XRef ID="Citrullinemia+Type+II/1652" DB="Genetic Alliance" />
                <XRef ID="MONDO:0016603" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Citrin deficiency can manifest in newborns or infants as neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD), in older children as failure to thrive and dyslipidemia caused by citrin deficiency (FTTDCD), and in adults as recurrent hyperammonemia with neuropsychiatric symptoms in citrullinemia type II (CTLN2). Often citrin deficiency is characterized by strong preference for protein-rich and/or lipid-rich foods and aversion to carbohydrate-rich foods. NICCD. Children younger than age one year have a history of low birth weight with growth restriction and transient intrahepatic cholestasis, hepatomegaly, diffuse fatty liver, and parenchymal cellular infiltration associated with hepatic fibrosis, variable liver dysfunction, hypoproteinemia, decreased coagulation factors, hemolytic anemia, and/or hypoglycemia. NICCD is generally not severe and symptoms often resolve by age one year with appropriate treatment, although liver transplantation has been required in rare instances. FTTDCD. Beyond age one year, many children with citrin deficiency develop a protein-rich and/or lipid-rich food preference and aversion to carbohydrate-rich foods. Clinical abnormalities may include growth restriction, hypoglycemia, pancreatitis, severe fatigue, anorexia, and impaired quality of life. Laboratory changes are dyslipidemia, increased lactate-to-pyruvate ratio, higher levels of urinary oxidative stress markers, and considerable deviation in tricarboxylic acid (TCA) cycle metabolites. One or more decades later, some individuals with NICCD or FTTDCD develop CTLN2. CTLN2. Presentation is sudden and usually between ages 20 and 50 years. Manifestations are recurrent hyperammonemia with neuropsychiatric symptoms including nocturnal delirium, aggression, irritability, hyperactivity, delusions, disorientation, restlessness, drowsiness, loss of memory, flapping tremor, convulsive seizures, and coma. Symptoms are often provoked by alcohol and sugar intake, medication, and/or surgery. Affected individuals may or may not have a prior history of NICCD or FTTDCD.</Attribute>
                <XRef ID="NBK1181" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10215" />
                <XRef ID="10215" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301360</ID>
                <ID Source="BookShelf">NBK1181</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG, ACT Sheet, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Citrullinemia.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, [Elevated Citrulline], Amino Acidemia/Urea Cycle Disorder, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Citrulline-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Elevated Citrulline: Amino Acidemia Algorithm, 2022</CitationText>
              </Citation>
              <XRef ID="247585" DB="Orphanet" />
              <XRef ID="C1863844" DB="MedGen" />
              <XRef ID="MONDO:0016603" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="1662" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="4809" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Neonatal intrahepatic cholestasis due to citrin deficiency</ElementValue>
                <XRef ID="MONDO:0011601" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neonatal-onset citrullinemia type II</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neonatal intrahepatic cholestasis caused by citrin deficiency</ElementValue>
                <XRef ID="Citrin+Deficiency/1648" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neonatal-onset citrullinemia type 2</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">NICCD</ElementValue>
                <XRef Type="MIM" ID="605814" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Citrin deficiency can manifest in newborns or infants as neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD), in older children as failure to thrive and dyslipidemia caused by citrin deficiency (FTTDCD), and in adults as recurrent hyperammonemia with neuropsychiatric symptoms in citrullinemia type II (CTLN2). Often citrin deficiency is characterized by strong preference for protein-rich and/or lipid-rich foods and aversion to carbohydrate-rich foods. NICCD. Children younger than age one year have a history of low birth weight with growth restriction and transient intrahepatic cholestasis, hepatomegaly, diffuse fatty liver, and parenchymal cellular infiltration associated with hepatic fibrosis, variable liver dysfunction, hypoproteinemia, decreased coagulation factors, hemolytic anemia, and/or hypoglycemia. NICCD is generally not severe and symptoms often resolve by age one year with appropriate treatment, although liver transplantation has been required in rare instances. FTTDCD. Beyond age one year, many children with citrin deficiency develop a protein-rich and/or lipid-rich food preference and aversion to carbohydrate-rich foods. Clinical abnormalities may include growth restriction, hypoglycemia, pancreatitis, severe fatigue, anorexia, and impaired quality of life. Laboratory changes are dyslipidemia, increased lactate-to-pyruvate ratio, higher levels of urinary oxidative stress markers, and considerable deviation in tricarboxylic acid (TCA) cycle metabolites. One or more decades later, some individuals with NICCD or FTTDCD develop CTLN2. CTLN2. Presentation is sudden and usually between ages 20 and 50 years. Manifestations are recurrent hyperammonemia with neuropsychiatric symptoms including nocturnal delirium, aggression, irritability, hyperactivity, delusions, disorientation, restlessness, drowsiness, loss of memory, flapping tremor, convulsive seizures, and coma. Symptoms are often provoked by alcohol and sugar intake, medication, and/or surgery. Affected individuals may or may not have a prior history of NICCD or FTTDCD.</Attribute>
                <XRef ID="NBK1181" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10214" />
                <XRef ID="10214" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301360</ID>
                <ID Source="BookShelf">NBK1181</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG, ACT Sheet, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Citrullinemia.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, [Elevated Citrulline], Amino Acidemia/Urea Cycle Disorder, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Citrulline-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Elevated Citrulline: Amino Acidemia Algorithm, 2022</CitationText>
              </Citation>
              <XRef ID="247598" DB="Orphanet" />
              <XRef ID="C1853942" DB="MedGen" />
              <XRef ID="MONDO:0011601" DB="MONDO" />
              <XRef Type="MIM" ID="605814" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9638" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6541" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Citrin deficiency</ElementValue>
                <XRef ID="MONDO:0016602" DB="MONDO" />
                <XRef ID="429735007" DB="SNOMED CT" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Citrin deficiency can manifest in newborns or infants as neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD), in older children as failure to thrive and dyslipidemia caused by citrin deficiency (FTTDCD), and in adults as recurrent hyperammonemia with neuropsychiatric symptoms in citrullinemia type II (CTLN2). Often citrin deficiency is characterized by strong preference for protein-rich and/or lipid-rich foods and aversion to carbohydrate-rich foods. NICCD. Children younger than age one year have a history of low birth weight with growth restriction and transient intrahepatic cholestasis, hepatomegaly, diffuse fatty liver, and parenchymal cellular infiltration associated with hepatic fibrosis, variable liver dysfunction, hypoproteinemia, decreased coagulation factors, hemolytic anemia, and/or hypoglycemia. NICCD is generally not severe and symptoms often resolve by age one year with appropriate treatment, although liver transplantation has been required in rare instances. FTTDCD. Beyond age one year, many children with citrin deficiency develop a protein-rich and/or lipid-rich food preference and aversion to carbohydrate-rich foods. Clinical abnormalities may include growth restriction, hypoglycemia, pancreatitis, severe fatigue, anorexia, and impaired quality of life. Laboratory changes are dyslipidemia, increased lactate-to-pyruvate ratio, higher levels of urinary oxidative stress markers, and considerable deviation in tricarboxylic acid (TCA) cycle metabolites. One or more decades later, some individuals with NICCD or FTTDCD develop CTLN2. CTLN2. Presentation is sudden and usually between ages 20 and 50 years. Manifestations are recurrent hyperammonemia with neuropsychiatric symptoms including nocturnal delirium, aggression, irritability, hyperactivity, delusions, disorientation, restlessness, drowsiness, loss of memory, flapping tremor, convulsive seizures, and coma. Symptoms are often provoked by alcohol and sugar intake, medication, and/or surgery. Affected individuals may or may not have a prior history of NICCD or FTTDCD.</Attribute>
                <XRef ID="NBK1181" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="20661" />
                <XRef ID="20661" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301360</ID>
                <ID Source="BookShelf">NBK1181</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG, ACT Sheet, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Citrullinemia.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, [Elevated Citrulline], Amino Acidemia/Urea Cycle Disorder, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Citrulline-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Elevated Citrulline: Amino Acidemia Algorithm, 2022</CitationText>
              </Citation>
              <XRef ID="247582" DB="Orphanet" />
              <XRef ID="C1997910" DB="MedGen" />
              <XRef ID="MONDO:0016602" DB="MONDO" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="26553" SubmissionDate="2013-09-24" DateLastUpdated="2013-09-27" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="603859.0003_CITRULLINEMIA, TYPE II, ADULT-ONSET" title="SLC25A13, 23-BP INS, NT1638_CITRULLINEMIA, TYPE II, ADULT-ONSET" />
        <ClinVarAccession Accession="SCV000026553" DateUpdated="2013-09-27" DateCreated="2013-04-04" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="1999-06-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In a patient with adult-onset type II citrullinemia (603471), Kobayashi et al. (1999) identified a 23-bp homozygous insertion in exon 16 of SLC25A13, 1638ins23, resulting in a frameshift at codon 554 and the addition of 16 new amino acids. A stop codon was introduced at position 570, leading to premature termination of the C terminus of citrin. The inserted sequence was apparently a tandem repeat of 23 bp from nucleotide 1638-1660 of SLC25A13 cDNA.</Attribute>
              <Citation>
                <ID Source="PubMed">10369257</ID>
              </Citation>
              <XRef DB="OMIM" ID="603471" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC25A13" />
          </GeneList>
          <Name>SLC25A13, 23-BP INS, NT1638</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">23-BP INS, NT1638</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="603859.0003" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">CITRULLINEMIA, TYPE II, ADULT-ONSET</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1376305" SubmissionDate="2018-09-19" DateLastUpdated="2018-12-15" DateCreated="2018-04-02">
        <ClinVarSubmissionID localKey="57026_000000" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000703906" DateUpdated="2018-12-15" DateCreated="2018-04-02" Type="SCV" Version="2" SubmitterName="Eurofins Ntd Llc (ga)" OrgID="500060" OrganizationCategory="laboratory" OrgAbbreviation="EGL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2016-11-18">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">EGL Classification Definitions 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/ahdynye1/egl_classification_definitions_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
              <Gender>mixed</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="3" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SingleHeterozygote" integerValue="3" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC25A13" />
          </GeneList>
          <VariantType>Duplication</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="7" alternateAllele="CCCGGGCAGCCACCTGTAATCTC" referenceAllele="-" start="95751241" stop="95751263" variantLength="23" />
            <GeneLocation>NM_014251.2:Ex16</GeneLocation>
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <Citation>
          <URL>http://www.egl-eurofins.com/emvclass/emvclass.php?approved_symbol=SLC25A13</URL>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB4534263</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="41254" SubmissionDate="2022-06-28" DateLastUpdated="2022-10-01" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="NM_014251.2:c.1638_1660dup|OMIM:603471" submittedAssembly="not applicable" />
        <ClinVarAccession Accession="SCV000041254" DateUpdated="2022-10-01" DateCreated="2013-04-04" Type="SCV" Version="3" SubmitterName="GeneReviews" OrgID="500062" OrganizationCategory="resource" OrgAbbreviation="GeneReviews" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no classification provided</ReviewStatus>
          <GermlineClassification>not provided</GermlineClassification>
          <Citation>
            <ID Source="BookShelf">NBK1181</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">10369257</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>1638ins23</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_014251.2:c.1638_1660dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN295299" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11612813</SubmissionName>
          <SubmissionName>SUB11808016</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7183382" SubmissionDate="2023-03-16" DateLastUpdated="2023-03-26" DateCreated="2023-03-26">
        <ClinVarSubmissionID localKey="NM_014251.2:c.1638_1660dup23|MedGen:C1863844" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003845174" DateUpdated="2023-03-26" DateCreated="2023-03-26" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-02-24">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">31450232</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21424115</ID>
          </Citation>
          <Comment>Variant summary: SLC25A13 c.1638_1660dup23 (p.Ala554GlyfsX17) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic within ClinVar (e.g. c.1799dup [p.Tyr600Ter], c.1813C&gt;T [p.Arg605Ter]). The variant allele was found at a frequency of 8.8e-05 in 251412 control chromosomes (gnomAD), predominantly at a frequency of 0.0012 within the East Asian subpopulation in the gnomAD database. This frequency is not significantly higher than estimated for a pathogenic variant in SLC25A13 causing Citrullinemia Type II (8.8e-05 vs 0.0012), allowing no conclusion about variant significance. c.1638_1660dup23 has been reported in the literature as a biallelic genotype in multiple individuals affected with Citrullinemia (e.g. Song_2011, Wang_2020). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Four ClinVar submitters have assessed the variant since 2014: all four classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC25A13" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_014251.2:c.1638_1660dup23</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1863844" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12956415</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7898027" SubmissionDate="2023-12-21" DateLastUpdated="2024-01-06" DateCreated="2024-01-06">
        <ClinVarSubmissionID localKey="1642603|Not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004226563" DateUpdated="2024-01-06" DateCreated="2024-01-06" Type="SCV" Version="1" SubmitterName="Mayo Clinic Laboratories, Mayo Clinic" OrgID="500068" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-08-11">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">10369257</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11432966</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19413723</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20927635</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23067347</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23901231</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30098237</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">34295780</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8105687</ID>
          </Citation>
          <Comment>PM2, PM3_strong, PVS1</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC25A13" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_014251.3:exon 16</GeneLocation>
          </Location>
          <OtherNameList>
            <Name>p.Ala554Glyfs*17</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_014251.3:c.1638_1660dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14104855</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3964988" SubmissionDate="2024-01-26" DateLastUpdated="2024-02-04" DateCreated="2021-11-29">
        <ClinVarSubmissionID localKey="357980dc2ec1a08930f617a13408661eeb66395e820a490e0cbb9c86e4829167|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002020659" DateUpdated="2024-02-04" DateCreated="2021-11-29" Type="SCV" Version="3" SubmitterName="Revvity Omics, Revvity" OrgID="167595" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-05-10">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_014251.3:c.1638_1660dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10694847</SubmissionName>
          <SubmissionName>SUB12926214</SubmissionName>
          <SubmissionName>SUB14173319</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2292628" SubmissionDate="2019-09-27" DateLastUpdated="2020-02-29" DateCreated="2020-02-29">
        <ClinVarSubmissionID localKey="NC_000007.13:g.95751241_95751263dupCCCGGGCAGCCACCTGTAATCTC|OMIM:605814" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001163572" DateUpdated="2020-02-29" DateCreated="2020-02-29" Type="SCV" Version="1" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" OrgAbbreviation="BCM: BMGL" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC25A13" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000007.13:g.95751241_95751263dupCCCGGGCAGCCACCTGTAATCTC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="605814" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>BG_GA_2018_SNVs_INDELS</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4984918" SubmissionDate="2023-02-19" DateLastUpdated="2023-02-25" DateCreated="2023-01-07">
        <ClinVarSubmissionID localKey="NM_014251.2:c.1638_1660dup|OMIM:605814" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV002546529" DateUpdated="2023-02-25" DateCreated="2023-01-07" Type="SCV" Version="2" SubmitterName="Genesolutions, Medical Genetics Institutes, Ho Chi Minh City, Vietnam" OrgID="508641" OrganizationCategory="laboratory" OrgAbbreviation="GS-MGI" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="508964" SubmitterName="Hepatology Department, National Childrenâ€™s Hospital" Type="secondary" OrganizationCategory="other" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-06-30">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">36599957</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC25A13" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_014251.2:c.1638_1660dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="605814" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11739646</SubmissionName>
          <SubmissionName>SUB12880035</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1857543" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2019-08-14">
        <ClinVarSubmissionID localKey="2496579|MedGen:C1997910" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000963171" DateUpdated="2024-02-14" DateCreated="2019-08-14" Type="SCV" Version="6" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-01-29">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">10369257</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">14680984</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27405544</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27405544</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Ala554Glyfs*17) in the SLC25A13 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SLC25A13 are known to be pathogenic (PMID: 10369257, 14680984, 27405544). This variant is present in population databases (rs80338725, gnomAD 0.1%). This premature translational stop signal has been observed in individuals with SLC25A13-related conditions (PMID: 27405544). ClinVar contains an entry for this variant (Variation ID: 6003). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC25A13" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000007.13:g.95751240_95751241insCCCGGGCAGCCACCTGTAATCTC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1997910" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12507860</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="8883134" SubmissionDate="2024-03-12" DateLastUpdated="2024-03-16" DateCreated="2024-03-16">
        <ClinVarSubmissionID localKey="Huaihuafyyck2024_023" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004800859" DateUpdated="2024-03-16" DateCreated="2024-03-16" Type="SCV" Version="1" SubmitterName="Neonatal Disease Screening Center, Medical Genetics Center, Huaihua City Maternal and Child Health Care Hospital" OrgID="509482" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>PVS1+PM3_VS+PP4</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="pmc">PMC4544753</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Miao</Ethnicity>
              <GeographicOrigin>China</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <NumberTested>1</NumberTested>
              <Gender>female</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SampleLocalID">Huaihuafyyck2024A_026</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC25A13" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_014251.2:c.1638_1660dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="605814" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14302371</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7859337" SubmissionDate="2024-06-05" DateLastUpdated="2024-06-17" DateCreated="2023-12-30">
        <ClinVarSubmissionID localKey="NM_014251.3:c.1638_1660dup|OMIM:603471" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004203613" DateUpdated="2024-06-17" DateCreated="2023-12-30" Type="SCV" Version="2" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" OrgAbbreviation="BCM: BMGL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-03-28">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_014251.3:c.1638_1660dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="603471" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GA_HC_20231102_20240331</SubmissionName>
          <SubmissionName>SUB13856327</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="41254" TraitType="Disease" MappingType="XRef" MappingValue="CN295299" MappingRef="MedGen">
        <MedGen CUI="CN295299" Name="Citrullinemia, type II, adult-onset" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4984918" TraitType="Disease" MappingType="XRef" MappingValue="605814" MappingRef="OMIM">
        <MedGen CUI="C1853942" Name="Neonatal intrahepatic cholestasis due to citrin deficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7183382" TraitType="Disease" MappingType="XRef" MappingValue="C1863844" MappingRef="MedGen">
        <MedGen CUI="C1863844" Name="Citrullinemia type II" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8883134" TraitType="Disease" MappingType="XRef" MappingValue="605814" MappingRef="OMIM">
        <MedGen CUI="C1853942" Name="Neonatal intrahepatic cholestasis due to citrin deficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2292628" TraitType="Disease" MappingType="XRef" MappingValue="605814" MappingRef="OMIM">
        <MedGen CUI="C1853942" Name="Neonatal intrahepatic cholestasis due to citrin deficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7859337" TraitType="Disease" MappingType="XRef" MappingValue="603471" MappingRef="OMIM">
        <MedGen CUI="CN295299" Name="Citrullinemia, type II, adult-onset" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="26553" TraitType="Disease" MappingType="Name" MappingValue="CITRULLINEMIA, TYPE II, ADULT-ONSET" MappingRef="Preferred">
        <MedGen CUI="CN295299" Name="Citrullinemia, type II, adult-onset" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3964988" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1376305" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1857543" TraitType="Disease" MappingType="XRef" MappingValue="C1997910" MappingRef="MedGen">
        <MedGen CUI="C1997910" Name="Citrin deficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7898027" TraitType="Disease" MappingType="Name" MappingValue="Not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

